首页> 美国卫生研究院文献>BMC Research Notes >Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status

【2h】

Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status

机译：吉非替尼单药治疗晚期非小细胞肺癌中国患者的疗效和安全性评估

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThis paper reports the outcome of gefitinib for Chinese advanced NSCLC patients with poor performance status (PS) at the Peking Union Medical College Hospital.

机译：背景本文报道了在北京联合医学院附属医院接受吉非替尼治疗的中国晚期NSCLC患者的研究成果，这些患者的表现状态（PS）较差。

著录项

期刊名称 BMC Research Notes
作者
Zhong Wei; Wang Mengzhao; Zhang Li; Li Longyun; Zhang Xiaotong;
展开▼
作者单位

展开▼
年(卷),期 2008(1),-1
年度 2008
页码 102
总页数 4
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status [J] . Shan Liu, Deqiang Wang, Bo Chen, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2011,第2期

机译：EGFR TKIs单药治疗与单药化疗以第三代细胞毒素为一线治疗对于晚期非小细胞肺癌和低下状态患者的安全性和有效性
2. Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer [J] . 中华医学杂志（英文版） . 2006,第001期

机译：吉非替尼单药治疗中国晚期非小细胞肺癌的疗效和安全性
3. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme [J] . Xin-Lin Mu, Long-Yun Li, Xiao-Tong Zhang, BMC Cancer . 2004,第1期

机译：吉非替尼（“ iressa”，zd1839）作为单药治疗在一系列中国晚期非小细胞肺癌患者中的安全性和有效性评估：同情使用计划的经验
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Evaluation of Symptom Management in Patients with Advanced Stage (IIIB and IV) Non-Small Cell Lung Cancer [D] . Mann, LaTonya E. 2018

机译：晚期（IIIB和IV）非小细胞肺癌患者症状管理的评估
6. Evaluation of safety and efficacy of gefitinib (iressa zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme [O] . Xin-Lin Mu, Long-Yun Li, Xiao-Tong Zhang, 2004

机译：吉非替尼（ iressazd1839）作为单药治疗在一系列中国晚期非小细胞肺癌患者中的安全性和疗效评估：同情使用计划的经验
7. Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status [O] . Longyun Li, Li Zhang, Mengzhao Wang, 2008

机译：吉非替尼单药治疗晚期非小细胞肺癌中国患者的疗效和安全性评估

Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status

摘要

著录项

相似文献

相关主题

期刊订阅